International Psoriasis Council

subscribe
Search
Advancing Knowledge. Enhancing Care.
subscribe
Search

Advancing Knowledge. Enhancing Care.

Psoriasis News

THE LATEST FROM IPC, INDUSTRY AND OTHERS
Results

Psoriasis and the Pandemic: Lessons Learned from PsoProtect

The spread of COVID-19 in early 2020 brought many concerns and questions about COVID-19 and psoriasis. To help address these concerns dermatologists and researchers created PsoProtect and PsoProtectMe — two global registries aimed at understanding the impact of the pandemic on people with psoriasis. Co-directors of PsoProtect and PsoProtectMe, Catherine Smith and Satveer Mahil, speak about the data collection process and findings from these global registries.

Read More
Friday, May 26, 2023

Commentary: Preclinical and Clinical Evidence for Suppression of Alcohol Intake by Apremilast

A host of factors is important to consider in the personalized treatment of psoriasis. It is advantageous if a treatment is effective in psoriasis and has beneficial effects on associated conditions. This recent literature publication has highlighted that apremilast, beyond its anti-psoriatic properties, positively impacts excessive alcohol consumption. Read the expert opinion of IPC Board Member Johann Gudjonsson, MD, PhD.

Read More
Tuesday, April 25, 2023
Commentary -Tiago Torres

Commentary: Trajectories and Prognosis after Discontinuation of Biologics due to Remission in Psoriasis – A Nationwide Cohort Study

The prognosis and maintenance of response after treatment discontinuation following remission lack proper characterization. Real-world data obtained from national registries may provide valuable insights into this clinical issue. Tiago Torres, MD, PhD, provides his expert opinion on a recent study that investigated epidemiological characteristics and disease markers during the first two years following cessation of biologic therapy due to remission in adult patients.

Read More
Tuesday, March 28, 2023
Commentary -Peter van de Kerkhof headshot

Commentary: Association of Apremilast with Vascular Inflammation and Cardiometabolic Function in Patients with Psoriasis: The VIP-A Phase 4, Open-label, Nonrandomized Clinical Trial

Recently, a study was conducted on the effect of apremilast on vascular inflammation and cardiometabolic functions with an impressively comprehensive set of markers for vascular inflammation and cardiometabolic disease. Peter van de Kerkhof, MD, PhD, provides his expert opinion on the overall conclusion and the implications of this study are discussed.

Read More
Thursday, December 15, 2022

Focus on Psoriasis: A Report from the European Academy of Dermatology and Venereology 31st Annual Congress (EADV)

The European Academy of Dermatology and Venereology (EADV) organized its 31st congress in Milano, Italy, under the parole “Designing the Future of Dermatology and Venereology.” The event took place from September 7 – 10, 2022, as a hybrid meeting with the option of attending virtually or in person. The following congress report includes fifteen summaries of presentations focusing on psoriasis. You can download the full report or read the summary.

Read More
Monday, November 7, 2022
GPA - Blog Post

The Global Psoriasis Atlas in Greenland – May 2022

The Global Psoriasis Atlas (GPA) is a joint project of the ILDS (International League of Dermatological Societies), IFPA (International Federation of Psoriasis Associations), and IPC (International Psoriasis Council) delivered by staff based at the University of Manchester. Its goal is to provide the benchmark on the burden of psoriasis in all countries and regions throughout the world using comprehensive epidemiological data to inform research, policy, and healthcare.

Read More
Wednesday, October 26, 2022
Filip Rob Commentary graphic

Commentary: Deucravacitinib Versus Placebo and Apremilast in Moderate to Severe Plaque Psoriasis: Efficacy and Safety Results from the 52-week, Randomized, Double-blinded, Placebo-controlled Phase 3 POETYK PSO-1 Trial

The United States Food and Drug Administration (FDA) has approved deucravacitinib to treat psoriasis. Recently, 52-week efficacy and safety data of deucravacitinib were compared and contrasted with placebo and apremilast. The outcome of this comparative study lends support for the position of deucravacitinib in the spectrum of treatments for psoriasis.

Read More
Friday, October 14, 2022
BIOMAP Collaboration Update A Systemic Review on Biomarkers

BIOMAP Collaboration Update: A Systemic Review on Biomarkers

Annually, the IPC Board selects a specific subject of importance and commissions a group of experts to conduct a best evidence review. In 2021, IPC supported the BIOMAP collaboration to complete a systematic review on biomarkers. Last month, two new lay summaries were published by BIOMAP on this project.

Read More
Tuesday, September 27, 2022

New Resources

Psoriasis Treatment and Chronic Infections (Webinar 2, 2023 Series)

VIEW

Psoriasis and Cancer: Epidemiologic Association (Webinar 2, 2023 Series)

VIEW

Psoriasis Treatment and Cancer: New Perspectives (Webinar 2, 2023 Series)

VIEW

Subscribe to the IPC Newsletter

We believe that psoriasis patients, no matter where they live in the world, no matter how complex their symptoms, should have access to the best care available to them. Please join us in making this possible.